Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin

AIDS

Volumn 7, Issue 9, 1993, Pages 1181-1184

  Koup, Richard A ^a,c   Brewster, Frank ^a   Grob, Peter ^b   Sullivan, John L ^a,d  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^d NONE   (United States)

Author keywords

Antiviral; Combination chemotherapy; HIV 1

Indexed keywords

ALPHA INTERFERON; ANTIGEN P24; ANTIVIRUS AGENT; CD4 IMMUNOGLOBULIN; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CD4 IMMUNOADHESINS; DRUG SYNERGISM; FEASIBILITY STUDIES; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMAN; IN VITRO; INTERFERON TYPE I, RECOMBINANT; NEVIRAPINE; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0027214287     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199309000-00005     Document Type: Article

References (35)

1. MITSUYA H, WEINHOLD KJ, FURMAN PA, ET AL.: 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985, 82:7096-7100.
2. MITSUYA H, BRODER S: Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA 1986, 83:1911-1915.
3. YARCHOAN R, MITSUYA H, THOMAS RV, ET AL.: In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science 1989, 245:412-415.
4. DEEN KC, MCDOUGAL SJ, INACKER R, ET AL.: A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 1988, 331:82-84.
5. FISHER RA, BERTONIS JM, MEIER W, ET AL.: HIV infection is blocked in vitro by recombinant soluble CD4. Nature 1988, 331:76-78.
6. HUSSEY RE, RICHARDSON NE, KOWALSKI M, ET AL.: A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 1988, 331:78-81.
7. SMITH DH, BYRN RA, MARSTERS SA, GREGORY T, GROOPMAN JE, CAPON DJ: Blocking of HFV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 1987, 238:1704-1707.
8. TRAUNECKER A, LUKE W, KARJALAINEN K: Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature 1988, 331:84-86.
9. CAPON DJ, CHAMOW SM, MORDENTI J, ET AL.: Designing CD4 immunoadhesins for AIDS therapy. Nature 1989, 337:525-531.
10. TRAUNECKER A, SCHNEIDER J, KIEFER H, AND KARJAIAINEN K: Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. Nature 1989, 339:68-70.
11. HO DD, HARTSHORN KL, ROTA TR, ET AL.: Recombinant human interferon alpha A suppresses HTLV-III replication in vitro. Lancet 1985, i:602-604.
12. YAMAMOTO JK, BARRÉ-SINOUSSI F, BOLTON V, PEDERSON NC, GARDNER MB: Human alpha- and beta-interferon but not gamma suppress the in vitro replication of LAV, HTLV-III and ARV-2. J Interferon Res 1986, 6:143-152.
13. MERLUZZI VJ, HARGRAVE KD, LABADIA M, ET AL.: Inhibition of HFV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science 1990, 250:1411-1413.
14. KOUP RA, MERLUZZI VJ, HARGRAVE KD, ET AL.: Inhibition of human immunodeficiency virus type 1 (HFV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis 1991, 163:966-970.
15. GOLDMAN ME, NUNBERG JH, O'BRIEN JA, ET AL.: Pyridone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA 1991, 88:6863-6867.
16. PAUWELS R, ANDRIES K, DESMYTER J, ET AL.: Potent and selective inhibition of HFV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990, 343:470-474.
17. CHEESEMAN SH, HATTOX S, MCLAUGHLIN M, ET AL.: Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993, 37:178-182.
18. RICHMAN D, ROSENTHAL AS, SKOOG M, ET AL.: BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicroh Agents Chemother 1991, 35:305-308.
19. RICHMAN D, SHIH CK, LOWY I, ET AL.: Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture Proc Natl Acad Sci USA 1991, 88:11241-11245.
20. HATTOX S: Pharmacokinetics of nevirapine alone and in combination with zidovudine. VIII International Confer ence on AIDS/'III STD World Congress. Amsterdam, July 1992 [abstract PoB3591].
21. DAAR ES, LI XL, MOUDGIL T, Ho DD: High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA 1990, 87:6574-6578.
22. DAAR ES, Ho DD: Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4. Am J Med 1991, (suppl) 90:22S-26S.
23. ASHKENAZI A, SMITH DH, MARSTERS SA, ET AL.: Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. Proc Natl Acad Sci USA 1991, 88:7056-7060.
24. LARDER BA, COATES KE, KEMP SD: Zidovudine-resistant human immunodeficiency virus selected by passage in tissue culture. J Virol 1991, 65:5232-5236.
25. GAO Q, GU Z, PARNIAK MA, LI X, WAINBERG MA: In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J Virol 1992, 66:12-19.
26. NUNBERG JH, SCHLEIF WA, BOOTS EJ, ET AL.: Viral resistance to human immunodeficiency virus type 1-specific pyridone reverse transcriptase inhibitors. J Virol 1991, 65:4887-4892
27. VASUDEVACHARI MB, BATTISTA C, LANE HC, ET AL.: Prevention of the spread of HIV-1 infection with non-nucleoside reverse transcriptase inhibitors. Virology 1992, 190:269-270.
28. RICHMAN DD: Loss of nevirapine activity associated with the emergence of resistance in clinical trials. VIII International Conference on AIDS/III STD World Congress. Amsterdam, July 1992 [abstract PoB3576].
29. HIRSCH MS, KAPLAN JC: Treatment of human immunodeficiency virus infections. Antimicrob Agents Chemother 1987, 31:839-843.
30. JOHNSON VA, BARLOW MA, MERRILL DP, CHOU T-C, HIRSCH MS: Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. J Infect Dis 1990, 161:1059-1067.
31. Ho DD, MOUDGIL T, ALAM M: Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989, 321:1621-1625.
32. CHOW Y-K, HIRSCH MS, MERRILL DP, ET AL.: Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 1993, 361:650-654.
33. CHOU T-C, TALALAY P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
34. MEDINA DJ, HSIUNG GD, MELLORS JW: Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro. Antimicrob Agents Chemother 1992, 36:1127-1130.
35. VOGT MW, HARTSHORN KL, FURMAN PA, ET AL.: Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987, 235:1376-1379.